Acquisition · Enterprise Software & IT

Tredence acquires US pharma analytics firm KMK Consulting

By Startup Enthusiast · 22 June 2026

What they do

Tredence helps large businesses use data and build AI-powered software

It acquired KMK Consulting, a US-based pharma and life sciences analytics firm, for an undisclosed sum

Healthcare and life sciences are expected to be 25% of Tredence revenue by 2028

Tredence, a data analytics company based in Bengaluru and San Jose, has acquired KMK Consulting.
KMK Consulting is a US-based firm founded in 2000 that specialises in pharma and life sciences analytics.
The financial terms of the acquisition were not disclosed.
KMK works with 8 of the world's top 10 pharma companies.
KMK's expertise includes commercial analytics, patient analytics, market access, real-world evidence, and market research.
Tredence contributes AI engineering, data platforms, and enterprise-scale deployment to the combined offering.
Tredence expects healthcare and life sciences to make up 25% of its revenue by 2028.

The pharma industry spends about $250 billion annually on R&D and a similar amount on commercialisation.
Analytics and AI services for life sciences are growing at a CAGR of 20% to 25%.
Tredence is targeting $1 billion in revenue by 2030 through organic growth and acquisitions.
Future acquisition focus areas include communications, media, and insurance.

Tredence helps large businesses use data and builds AI-powered software for customer behaviour, operations, and sales.
Its AI stack includes the decision intelligence platform Atom.AI, the ML platform ML Works, and agentic AI.
Tredence's annual revenue for calendar year 2026 is roughly $250 million.
The company is on track to grow about 45% this year.
KMK Consulting specialises in commercial analytics, patient analytics, market access, real-world evidence, and market research.
KMK works with 8 of the world's top 10 pharma companies.

Tredence is targeting $1 billion in revenue by 2030 through organic growth and acquisitions.
The company may explore a fresh fundraise in calendar year 2027.
Tredence may evaluate an IPO in the future, but listing is 'an option, not a compulsion'.
Future acquisition focus areas include communications, media, and insurance.